

For Health Professionals Who Care For Cancer Patients

Inside This Issue:

- **Editor's Choice – New Programs:** Regorafenib for Advanced Hepatocellular Carcinoma (UGIREGO)
- **Provincial Systemic Therapy Program** – Education Bulletin Now Available on BC Cancer Website, BC Cancer SHOP Launched on June 24th
- **Benefit Drug List** – New: UGIREGO; Deleted: MOHDMTX
- **Cancer Drug Manual** – Revised: Fulvestrant, Irinotecan Liposome, Chemotherapy Preparation and Stability Chart Updates – Bleomycin, Bortezomib, Busulfan, Cisplatin, Cytarabine, Fluorouracil, Irinotecan, Leucovorin, Methotrexate, Oxaliplatin, Pemetrexed, Topotecan, Zoledronic Acid; Deleted: Amifostine
- **List of New and Revised Protocols, Provincial Pre-Printed Orders and Patient Handouts** – New: UGIREGO, UMYDARBD, UMYDARLD; Revised: BRAJACT, BRAJACTG, BRAJACTT, BRAJACTTG, BRAJACTW, BRAJCAP, UBRAJDAC, BRAJDCARBT, BRAJFCD, BRAJFCDT, BRAJLHRHAI, UBRAJPAM, BRAJTR, BRAJZOL2, BRAJZOL5, UBRAVPALAI, BRAVPAM, BRAVPTRAD, BRAVPTRAT, BRAVTR, BRAVZOL, CNAJ12TZRT, CNAJTZRT, CNBEV, CNCCNU, CNELTZRT, CNQUIN, GIAVTZCAP, GICIRB, GIFFOXB, GIPE, GOVCAD, UGUAVIPNI, UGUAVNIV, UGUAVNIV4, UHNAVIV, UHNAVIV4, ULUAVOSI, LUAVPMTN, LULAPE2RT, LULAPER, ULYRICE, UMYCARLD, UMYDARBD, UMYDARLD
- **Website Resources and Contact Information**

EDITOR'S CHOICE

NEW PROGRAMS

Effective 01 July 2019, the BC Cancer Provincial Systemic Therapy Program has approved the following treatment program:

Gastrointestinal:

Regorafenib for Advanced Hepatocellular Carcinoma (HCC) (UGIREGO) – The BC Cancer Gastrointestinal Tumour Group is introducing regorafenib for advanced HCC in patients who were previously treated with, and tolerated, a minimum sorafenib dose of 400 mg once daily.¹ This new treatment will fill an unmet need as there was no previous standard treatment for HCC after disease progression on sorafenib. A BC Cancer Compassionate Access Program (CAP) approval is required.

Regorafenib is a multiple receptor tyrosine kinase inhibitor that blocks the activity of protein kinases involved in angiogenesis, oncogenesis, metastasis and tumour immunity.² A phase III randomized, placebo-controlled trial (RESORCE) demonstrated improvement in overall survival (mOS 10.6 mo vs. 7.8 mo, HR 0.63, 95% CI 0.50-0.79) and progression-free survival (mPFS 3.1 mo vs. 1.5 mo, HR 0.46, 95% CI 0.37-0.56). Treatment-related adverse effects were more frequent in the regorafenib arm, and included hand-foot skin reactions, diarrhea, fatigue, hypertension and hyperbilirubinemia. Patients on regorafenib were twice as likely to have a dose modification (67% vs 31%) than patients on placebo. However, no significant differences were observed in health-related quality of life measures between the two groups.

EDITOR'S CHOICE

References:

1. Pan-Canadian Oncology Drug Review (pCODR) Expert Review Committee (pERC). Final recommendation for regorafenib (Stivarga®) for hepatocellular carcinoma (HCC). 18 April 2018.
2. Bruix J, Qin S, Merle P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomized, double-blind, placebo-controlled, phase 3 trial. *Lancet* 2017;389:56-66.

PROVINCIAL SYSTEMIC THERAPY PROGRAM UPDATE

EDUCATION BULLETIN NOW AVAILABLE ON BC CANCER WEBSITE

The BC Cancer Provincial Systemic Therapy Program has now launched its Education Bulletin on the BC Cancer website at: <http://www.bccancer.bc.ca/health-professionals/clinical-resources/systemic-therapy/education-bulletin>. Education Bulletins are intended to educate health care staff on new treatment programs planned for implementation at BC Cancer in the near future, and are currently targeting the Nursing discipline in the initial phase of implementation. Nursing personnel who are interested in receiving the Education Bulletin may contact the Provincial Systemic Therapy Program at ProvincialSystemicOffice@bccancer.bc.ca to be added to the email distribution list.

For further information about the Education Bulletin initiative, please see the [May 2019](#) issue of the Systemic Therapy Update.

BC CANCER SHARED HEALTH ORGANIZATIONS PORTAL (SHOP) LAUNCHED ON JUNE 24TH!

[Shared Health Organizations Portal](#), also known as SHOP, is the new home for BC Cancer- and PHSA-wide policies and procedures. As of June 24th, BC Cancer went live with provincial program documents on SHOP, including Provincial Systemic Therapy Program policies. This portal is accessible from anywhere. Although Communities Oncology Network sites will have full access to SHOP, Systemic Therapy policies will continue to be accessible on the BC Cancer website. Please note that SHOP is a portal for policies and decision support tools only and will NOT include documents such as chemotherapy protocols, Cancer Drug Manual monographs, etc. – these documents will continue to be available on the BC Cancer website.

Programs currently on SHOP include – Provincial Nursing, Provincial Pharmacy, Systemic Therapy, Radiation Therapy, Breast Screening, Health Information Management, Patient Experience Program, Pain and Symptom Management/Palliative Care, and BC Cancer-wide policies, with more to come in the future.

Please visit the [SHOP POD page](#) for tips and tricks on how to use SHOP. Any questions about SHOP can be directed to the BC Cancer Policy Office at policyoffice@bccancer.bc.ca or 604-877-6000 (ext 672881).

BENEFIT DRUG LIST

NEW PROGRAMS

Effective 01 July 2019, the following treatment program has been added to the BC Cancer [Benefit Drug List](#):

Protocol Title	Protocol Code	Benefit Status
Treatment of Advanced Hepatocellular Carcinoma using Regorafenib	UGIREGO	Restricted

DELETED PROGRAMS

Effective 1 July 2019, the following treatment program has been deleted from the BC Cancer [Benefit Drug List](#):

Protocol Title	Protocol Code	Benefit Status
Treatment of Meningeal Disease (Miscellaneous Tumour Origins) using High-Dose Methotrexate with Leucovorin Rescue	MOHDMTX	Class I

CANCER DRUG MANUAL

REVISED MONOGRAPHS AND PATIENT HANDOUTS

Highlights of key changes and/or updates to the Monographs, Patient Handouts and Chemotherapy Preparation and Stability Chart are listed below:

Fulvestrant Monograph and Patient Handout:

- Underwent complete revision with expert review provided by Dr. Vanessa Bernstein (Medical Oncologist, BC Cancer Breast Tumour Group) and Megan Darbyshire (Pharmacist, BC Cancer – Prince George)
- Highlights of key changes include:
 - Injection site events (e.g. sciatica, neuralgia, peripheral neuropathy) have been reported and are associated with administration to the dorsogluteal region, which is in close proximity to the sciatic nerve and large blood vessels
 - Hypersensitivity reactions (including angioedema and urticaria) are reported in at least 10% of patients and may occur shortly after or up to several days after fulvestrant injection
 - Severe and sometimes fatal hepatic failure, hepatic necrosis, and hepatitis have been rarely reported (including cases up to six months after initiation of fulvestrant)

Irinotecan Liposome Interim Monograph and Chemotherapy Preparation and Stability Chart:

- *Supply and Storage* – deleted Health Canada Special Access Programme (SAP) formulation, updated commercial supply

CANCER DRUG MANUAL

Chemotherapy Preparation and Stability Chart updated to reflect current drug contracts for the following drugs:

- Bleomycin
- Bortezomib
- Busulfan
- Cisplatin
- Cytarabine
- Fluorouracil
- Irinotecan
- Leucovorin
- Methotrexate
- Oxaliplatin
- Pemetrexed
- Topotecan
- Zoledronic acid

DELETED MONOGRAPHS AND PATIENT HANDOUTS

The **Amifostine Monograph** and **Patient Handout** have been deleted, and removed from the **Chemotherapy Preparation and Stability Chart**.

LIST OF REVISED PROTOCOLS, PRE-PRINTED ORDERS AND PATIENT HANDOUTS

BC Cancer Protocol Summaries, Provincial Pre-Printed Orders (PPPOs) and Patient Handouts are revised periodically. New, revised or deleted protocols, PPPOs and patient handouts for this month are listed below. Protocol codes for treatment requiring BC Cancer Compassionate Access Program approval are prefixed with the letter “U”.

NEW PROTOCOLS, PPPOs AND PATIENT HANDOUTS (AFFECTED DOCUMENTS ARE CHECKED)

CODE	Protocol	PPPO	Patient Handout	Protocol Title
UGIREGO	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Treatment of Advanced Hepatocellular Carcinoma using Regorafenib
UMYDARBD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	Treatment of Relapsed and Refractory Multiple Myeloma with Daratumumab in Combination with Bortezomib and Dexamethasone with or without Cyclophosphamide
UMYDARLD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	Treatment of Relapsed and Refractory Multiple Myeloma with Daratumumab in Combination with Lenalidomide and Dexamethasone

REVISED PROTOCOLS, PPPOs AND PATIENT HANDOUTS (AFFECTED DOCUMENTS ARE CHECKED)

CODE	Protocol	PPPO	Patient Handout	Changes	Protocol Title
BRAJACT	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Protocol title, Eligibility and Institutional name updated</i>	Neoadjuvant or Adjuvant Therapy for Breast Cancer using Doxorubicin and Cyclophosphamide followed by Paclitaxel

REVISED PROTOCOLS, PPOs AND PATIENT HANDOUTS (AFFECTED DOCUMENTS ARE CHECKED)					
CODE	Protocol	PPO	Patient Handout	Changes	Protocol Title
BRAJACTG	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Protocol title and Institutional name updated</i>	Neoadjuvant or Adjuvant Therapy for Breast Cancer using Dose-Dense Therapy: Doxorubicin and Cyclophosphamide followed by Paclitaxel
BRAJACTT	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Protocol title updated</i>	Neoadjuvant or Adjuvant Therapy for Breast Cancer using Doxorubicin and Cyclophosphamide followed by Paclitaxel and Trastuzumab (HERCEPTIN)
BRAJACTTG	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Protocol title updated</i>	Neoadjuvant or Adjuvant Therapy for Breast Cancer using Dose-Dense Therapy: Doxorubicin and Cyclophosphamide Followed by Paclitaxel and Trastuzumab (HERCEPTIN)
BRAJACTW	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Protocol title and Eligibility updated</i>	Neoadjuvant or Adjuvant therapy for Early Breast Cancer using Doxorubicin and Cyclophosphamide Followed by Weekly Paclitaxel
BRAJCAP	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Eligibility clarified</i>	Therapy of Adjuvant Breast Cancer using Capecitabine
UBRAJDAC	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Protocol title and Institutional name updated</i>	Neoadjuvant or Adjuvant Therapy for Breast Cancer using Cyclophosphamide, Doxorubicin and Docetaxel
BRAJDCARBT	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Protocol title updated</i>	Neoadjuvant or Adjuvant Therapy for Breast Cancer using Docetaxel, Carboplatin, and Trastuzumab (HERCEPTIN)
BRAJFEC D	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Protocol title and Institutional name updated</i>	Neoadjuvant or Adjuvant Therapy for Breast Cancer using Fluorouracil, Epirubicin, Cyclophosphamide and Docetaxel
BRAJFEC DT	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Protocol title updated</i>	Neoadjuvant or Adjuvant Therapy for Breast Cancer using Fluorouracil, Epirubicin and Cyclophosphamide Followed by Docetaxel and Trastuzumab (HERCEPTIN)
BRAJLHRHAI	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Protocol title and Institutional name updated</i>	Neoadjuvant or Adjuvant Ovarian Suppression and Aromatase Inhibitor in Premenopausal Women with High-Risk Early Stage Breast Cancer
UBRAJPAM	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Timing of lab tests clarified</i>	Adjuvant Treatment of Post-Menopausal Women using Pamidronate
BRAJTR	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Timing of cardiac monitoring clarified</i>	Adjuvant Therapy for Breast Cancer using Trastuzumab (HERCEPTIN) Following the Completion of Chemotherapy (Sequential)
BRAJZOL2	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Timing of lab tests clarified</i>	Adjuvant Treatment of Post-Menopausal Women using 3-Monthly Zoledronic Acid

REVISED PROTOCOLS, PPPOs AND PATIENT HANDOUTS (AFFECTED DOCUMENTS ARE CHECKED)

CODE	Protocol	PPPO	Patient Handout	Changes	Protocol Title
BRAJZOL5	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Timing of lab tests clarified</i>	Adjuvant Treatment of Post-Menopausal Women using 6-Monthly Zoledronic Acid
UBRAVPALAI	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Lab tests clarified</i>	Therapy of Advanced Breast Cancer using Palbociclib and Aromatase Inhibitor with or without LHRH Agonist
BRAVPAM	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Eligibility and timing of lab tests clarified, Protocol title revised</i>	Prevention of Skeletal Related Events Secondary to Breast Cancer Metastases using Pamidronate
BRAVPTRAD	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Treatment cycles clarified</i>	Palliative Therapy for Metastatic Breast Cancer using Pertuzumab, Trastuzumab (HERCEPTIN), and Docetaxel as First-Line Treatment for Advanced Breast Cancer
BRAVPTRAT	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Treatment cycles clarified</i>	Palliative Therapy for Metastatic Breast Cancer using Pertuzumab, Trastuzumab (HERCEPTIN), and Paclitaxel as First-Line Treatment for Advanced Breast Cancer
BRAVTR	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Eligibility clarified, Institutional name updated</i>	Palliative Therapy for Metastatic Breast Cancer using Trastuzumab (HERCEPTIN)
BRAVZOL	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Timing of lab tests clarified</i>	Treatment of Acute Bone Pain Secondary to Breast Cancer Metastases using IV Zoledronic Acid
CNAJ12TZRT	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<i>Dose Modifications clarified, Institutional name and logo updated</i>	Concomitant (Dual Modality) and 12 Cycles of Adjuvant Temozolomide for Newly Diagnosed Astrocytomas and Oligodendrogliomas with Radiation
CNAJ TZRT	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<i>Dose Modifications clarified, Institutional name and logo updated</i>	Concomitant (Dual Modality) and Adjuvant Temozolomide for Newly Diagnosed Malignant Gliomas with Radiation
CNBEV	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<i>Dose Modifications clarified, Institutional name and logo updated</i>	Palliative Therapy for Recurrent Malignant Gliomas using Bevacizumab with or without Concurrent Etoposide or Lomustine
CNCCNU	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Dose Modifications clarified</i>	Lomustine (CCNU) for Treatment of Recurrent Malignant Brain Tumours

REVISED PROTOCOLS, PPPOs AND PATIENT HANDOUTS (AFFECTED DOCUMENTS ARE CHECKED)

CODE	Protocol	PPPO	Patient Handout	Changes	Protocol Title
CNELTZRT	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<i>Dose Modifications clarified, Institutional name and logo updated</i>	Treatment of Elderly Newly Diagnosed Glioma Patient with Concurrent and Adjuvant Temozolomide and Radiation Therapy
CNQUIN	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Institutional name updated</i>	Suppressive Therapy for Pituitary Adenomas using Quinagolide
GIAVTZCAP	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<i>Dose Modification clarified, Protocols, PPPOs and Handouts harmonized</i>	Palliative Therapy of Metastatic Neuroendocrine Cancer using Temozolomide and Capecitabine
GICIRB	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Treatment duration clarified</i>	Palliative Combination Chemotherapy for Metastatic Colorectal Cancer using Irinotecan, Bevacizumab and Capecitabine
GIFFOX B	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Treatment duration clarified</i>	Palliative Combination Chemotherapy for Metastatic Colorectal Cancer using Oxaliplatin, Fluorouracil, Leucovorin and Bevacizumab
GIPE	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<i>Treatment duration clarified</i>	Palliative Therapy of Neuroendocrine Tumours using Cisplatin and Etoposide
GOOVCAD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Carboplatin dose escalation removed</i>	Primary Treatment with Visible or No Visible Residual Tumour (Moderate, High, or Extreme Risk) or Treatment at Relapse of Invasive Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer, using Carboplatin and Docetaxel
UGUAVIPNI	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Toxicities management formatted, acetaminophen dose clarified</i>	Treatment of Metastatic or Advanced Renal Cell Carcinoma using Ipilimumab and Nivolumab
UGUAVNIV	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Toxicities management formatted, acetaminophen dose clarified</i>	Treatment of Metastatic or Advanced Renal Cell Carcinoma using Nivolumab
UGUAVNIV4	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Toxicities management formatted, acetaminophen dose clarified</i>	Treatment of Metastatic or Advanced Renal Cell Carcinoma using 4-Weekly Nivolumab
UHNAV NIV	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Toxicities management formatted, acetaminophen dose clarified</i>	Palliative Therapy for Unresectable, Platinum-Refractory, Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck using Nivolumab

REVISED PROTOCOLS, PPPOs AND PATIENT HANDOUTS (AFFECTED DOCUMENTS ARE CHECKED)					
CODE	Protocol	PPPO	Patient Handout	Changes	Protocol Title
UHNAVIV4	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Toxicities management formatted, acetaminophen dose clarified</i>	Palliative Therapy for Unresectable, Platinum-Refractory, Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck using 4-Weekly Nivolumab
ULUAVOSI	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Title updated (PO designation removed)</i>	Treatment of EGFR T790M Mutation-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) with Osimertinib
LUAVPMTN	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Eligibility clarified</i>	Maintenance Therapy of Advanced Non-Small Cell Lung Cancer (NSCLC) with Pemetrexed
LULAPE2RT	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<i>Institutional name and Tests updated</i>	Treatment of Locally Advanced Non-Small Cell Lung Cancer using Alternative Dosing of Cisplatin and Etoposide with Radiation Therapy
LULAPERT	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<i>Institutional name and Tests updated</i>	Treatment of Locally Advanced Non-Small Cell Lung Cancer using Cisplatin and Etoposide with Radiation Therapy
ULYRICE	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Tests clarified</i>	Treatment of Relapsed or Refractory Advanced Stage Aggressive B-Cell Non-Hodgkin's Lymphoma with Ifosfamide, Carboplatin, Etoposide and Rituximab
UMYCARLD	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Dispensing quantity clarified</i>	Therapy of Multiple Myeloma using Carfilzomib, Lenalidomide with Dexamethasone
UMYDARBD	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Premedications, Eligibility, Monitoring, PPO reformatted</i>	Treatment of Relapsed and Refractory Multiple Myeloma with Daratumumab in Combination with Bortezomib and Dexamethasone with or without Cyclophosphamide
UMYDARLD	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Premedications, Eligibility, Monitoring, PPO reformatted</i>	Treatment of Relapsed and Refractory Multiple Myeloma with Daratumumab in Combination with Lenalidomide and Dexamethasone

WEBSITE RESOURCES AND CONTACT INFORMATION

CONTACT INFORMATION	PHONE	FAX	EMAIL
Systemic Therapy Update Editor	604-877-6000 x 673028		bulletin@bccancer.bc.ca
Provincial Systemic Therapy Program	604-877-6000 x 672247		mclin@bccancer.bc.ca
To update contact information of any CON sites, please contact:			bulletin@bccancer.bc.ca
Oncology Drug Information	604-877-6275		druginfo@bccancer.bc.ca
Nurse Educators	604-877-6000 x 672638		nursinged@bccancer.bc.ca
Library/Cancer Information	604-675-8003 Toll Free 888-675-8001 x 8003		requests@bccancer.bc.ca
Pharmacy Professional Practice	604-877-6000 x 672247		mclin@bccancer.bc.ca
Provincial Professional Practice Nursing			BCCancerPPNAdmin@ehcnet.phsa.ca
OSCAR	888-355-0355	604-708-2051	oscar@bccancer.bc.ca
Compassionate Access Program (CAP)	604-877-6277	604-708-2026	cap_bcca@bccancer.bc.ca
Pharmacy Oncology Certification	250-712-3900 x 686820		rxchemocert@bccancer.bc.ca
BC Cancer-Abbotsford	604-851-4710 Toll Free 877-547-3777		
BC Cancer-Prince George (Centre for the North)	250-645-7300 Toll Free 888-775-7300		
BC Cancer-Surrey	604-930-2098 Toll Free 800-523-2885		
BC Cancer-Kelowna	250-712-3900 Toll Free 888-563-7773		
BC Cancer-Vancouver	604-877-6000 Toll Free 800-663-3333		
BC Cancer-Victoria	250-519-5500 Toll Free 800-670-3322		

EDITORIAL REVIEW BOARD

Sally Waignein, PharmD (Editor)
 Anne Dar Santos, PharmD (Assistant Editor)
 Mario de Lemos, PharmD, MSc(Oncol)

Caroline Lohrisch, MD
 Ava Hatcher, RN, MN, CON(c)
 Naren Bollipalli, BSc(Pharm)